Nuchev Pty Ltd · ASX:NUC
Nuchev Pty — Shareholder Meeting (November 2025)
16 slides from Nuchev Pty's shareholder meeting presentation, Nov 28, 2025
Slide 1: ASX Announcement: Nuchev Limited AGM
ASX ANNOUNCEMENT | 28 November 2025 Nuchev Limited (ASX:NUC) (Nuchev or the Company) For personal use only For further information please contact: Nathan Cheong Chief Executive Officer nathan.cheong@nuchev.com.au Nuchev is an Australian- Bio Practica and Medicine Tree and a number of globally recogn
Slide 2: AGM agenda and strategic themes
ASX ANNOUNCEMENT | 28 November 2025 Nuchev Limited | AGM | 12.00pm AEDT | 28 November 2025 For personal use only 1. Growing our global presence 2. Accelerating innovation and new product development 3. Strengthening our brands 4. Driving sales growth with better marketing and digital enablement 5. M
Slide 3: For personal use only
ASX ANNOUNCEMENT | 28 November 2025 For personal use only
Slide 4: 2025 Annual General Meeting June 2025 Financial Year
2025 Annual General Meeting 30 June 2025 Financial Year
Slide 5: Vision, Mission and Purpose
Vision To lead globally as a House of Brands transforming wellness, longevity, and future-focused solutions. e e Mission We turn consumer insight into demand-led products, creative strategies into retail/practitioner growth, and every brand touchpoint into an unfair advantage for Nuchev. We partner
Slide 6: Business Highlights
Business Highlights > Refreshed business strategy, 3-year plan and focus on driving the business to profitability Group revenue: of $22.9m up $12.0m or 110% pcp’, reflecting strong sales growth in ANZ Retail, China CBEC and Vietnam for Oli6® Nutritionals? and a significant uplift delivered by the ac
Slide 7: FY25 Results Update
FY25 Results Update >, Group revenue’ of $22.9m in FY25 up $12.0m or 110% pcp’, reflecting strong sales Sales Revenue (5 millions) growth of Oli6® Nutritionals of $3.4m or 31% pep in ANZ Retail, China CBEC and 25.0 22.9 entry into the Vietnamese market in H2 FY25 combined with Practitioner channel 2
Slide 8: FY25 Adjusted EBITDA
FY25 Adjusted EBITDA s Revenue 22.9 10.9 Cost of sales (excluding raw material sales) (11.9) (7.0) 2. Profit 11.0 3.9 Ofyibution, warehouse and logistics expenses (0.8) (0.4) Marketing and selling expenses (4.2) (3.0) Net Contribution Margin 6.0 0.5 “ty Ratio : Oli6 Nutritionals Sales 26% 5% Grploym
Slide 9: Continued improvement in operating cash outflows
Continued improvement in operating cash outflows > Qi Q2 Q3 Q4 Qi Q2 Q3 Q4 Qi Q2 Q3 Q4 Ql Q2 Qs a4 — 22.22 22 22 23 #23 23 23 24 #24 #24 #24 «#225 FY25 25 25 cn Oo @> = ° =1000 Cc fon Y) — aye os S=r000 Oo LL -5000 Notes: Adjusted Cash Used in Operations has been normalised to exclude business combi
Slide 10: Balance Sheet
Balance Sheet 30 Jun 2025 30 Jun 2024 Cash holding of $3.6m @ash and short term deposits 3.6 7.6 ‘Spo and other receivables 3.0 2.2 °* Closing cash position $3.6m at 30 June 2025, with the reduction from 30 June 2024 primarily relating to cash used in operations and one-off cash costs associated wit
Slide 11: Key Strategic Priorities
Key Strategic Priorities Fer personal.use only Global Expansion and Market Relevance: Unlock international potential by: a) Further expanding Oli6® in South-East Asia building on current success in ANZ, China and Vietnam b) Tapping into adjacent categories to broaden Oli6’s health ecosystem Innovati
Slide 12: Q1 FY26 Update
Q1 FY26 Update , Group revenue! of $6.5m in Q1 FY26, up $1.5m or +30% pcp’, with our entry into the Vietnam market in March 2025 contributing sales of $0.6m in Q1 FY26 Q1 FY26 revenue from Oli6® Nutritionals in ANZ and China CBEC of $4.0m up $1.4m or +56% pcp Q1 FY26 revenue from bWellness of $2.6m
Slide 13: Q1 FY26 Group Revenue Comparison
Q1 FY26 Group Revenue Comparison For personal use only 7.0 6.0 5.0 40 3.0 2.0 1.0 6.1 ~ 2.5 QiFY25 Nuchev Group Revenue ($ m) (unaudited) 5.4 eu! 35 Q2 FY25 Q3 FY25 Oli6 Nutritionals m Practitioner 4.6 Q4FY25 6.5 4.0 Q1FY26 10
Slide 14: Appendix: Adjusted EBITDA reconciliation
Appendix 1 ~fa) Adjusted EBITDA reconciliation: (ipairment of assets 0.0 0.1 jluct Obsolescence & provisioning 0.0 0.3 Bares combination costs on acquisition 0.0 1.0 Out Payment Linked to Business Acquisition 0.4 0.0 cognition of deferred consideration for business “ERbinstion (0.4) 0.0 (targin on r
Slide 15: Disclaimer
Disclaimer - For personal use only This presentation has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. In particular, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities
Slide 16: For personal use only
Oli R i tree BioPractica GOAT MILK 13